RxDoctor Payments Data

Matthew Oltmanns, MD

Retina Specialist · Birmingham, ALNPI 1063603322

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by AbbVie at 46.4% of the total. Reporting peaked in 2024 at $176 and has fallen 87.7% since, to $22 in 2025. That places this record below the midpoint for retina specialist clinicians in AL, where the typical reported total is $919.

$412in general payments, 2019–2025

Across 13 payments — averaging $31.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$192
  • Regeneron Healthcare Solutions, Inc.$122
  • Carl Zeiss Meditec USA, Inc.$56
  • Genentech USA, Inc.$43

What the payments were for

  • Food & beverage$412100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$412 in reported general payments places this provider in the 25th percentile of 21 retina specialist providers in Alabama.

See all retina specialist providers in Alabama

Medicare billing

Part B allowed, 2024
$2,035,012
Medicare patients
826
Services billed
17,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate309$18,084
Bromfenac Sodium52$6,263
Alphagan PBrimonidine Tartrate14$5,106
Difluprednate39$4,158
Loteprednol Etabonate16$3,715
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$3,532
Ketorolac Tromethamine74$2,583
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat127$2,204
Brimonidine Tartrate128$1,835
Ofloxacin126$1,665
Atropine Sulfate20$1,131
Timolol Maleate70$1,112
Latanoprost67$665
ValacyclovirValacyclovir Hcl11$514
MoxifloxacinMoxifloxacin Hcl18$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P$192$5,10614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 21 retina specialist providers in Alabama.

Other retina specialist in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →